| A PILOT Study on LSGB vs EMB in the Diagnosis of Cardiac Transthyretin Amyloidosis (NCT05375279) | Unity Health Toronto | 2022-06-15 |
| MargheRITA (Remote Intelligence for Therapeutic Adherence) (NCT05260203) | Advice Pharma Group srl | 2022-06-04 |
| Identification of Clinically Significant Markers of ATTRv in Pre-symptomatic Mutation Carriers. (NCT05754099) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2022-03-01 |
| A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (NCT05250973) | Janssen Research & Development, LLC | 2022-03-01 |
| carDIo-ttranSSfOrm nucLEar Imaging Study (NCT05259072) | Oregon Health and Science University | 2022-01-19 |
| AL Amyloidosis and Anti-CD38-Daratunumab (NCT06571864) | University of Turin, Italy | 2022-01-02 |
| Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease (NCT04984330) | Weill Medical College of Cornell University | 2021-12-01 |
| A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis (NCT05235269) | Attralus, Inc. | 2021-11-30 |
| Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis (NCT05199337) | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 2021-11-30 |
| A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis (NCT05263817) | Zhejiang University | 2021-10-08 |
| Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy (NCT04985734) | University Hospital, Antwerp | 2021-10-01 |
| Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) (NCT04991103) | University of Alabama at Birmingham | 2021-09-22 |
| Increasing Amyloidosis Awareness and Diagnosis Through Programmatic Imaging, Blood/Urine Testing and Pathology (NCT04983433) | Beneficência Portuguesa de São Paulo | 2021-08-05 |
| CLearing Alzheimer's Disease Molecular Pathology Without Medications (NCT04913454) | University Hospital, Geneva | 2021-08-01 |
| Early Detection of Cardiac Amyloidosis (NCT05010980) | Heinrich-Heine University, Duesseldorf | 2021-08-01 |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH (NCT05283993) | Peking University First Hospital | 2021-07-01 |
| A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects (NCT04769479) | Eidos Therapeutics, a BridgeBio company | 2021-03-28 |
| Study of Olfactory Disorders in Patients With Cardiac Amyloidosis (NCT04661800) | Assistance Publique - Hôpitaux de Paris | 2021-03-22 |
| Screening for Amyloidosis Before Aortic Valve Elective Replacement (NCT04869631) | Charite University, Berlin, Germany | 2021-02-01 |
| Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis (NCT04636684) | University Hospital, Toulouse | 2020-12-01 |
| Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF (NCT05577819) | Massachusetts General Hospital | 2020-10-02 |
| DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies (NCT04265040) | University Hospital Heidelberg | 2020-08-18 |
| Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry (NCT05556928) | University of Alabama at Birmingham | 2020-07-21 |
| A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders (NCT03959358) | University Health Network, Toronto | 2020-07-03 |
| Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Bidimensional Shear Wave Elastography) in Patients With Transthyretin Amyloidosis (NCT04456582) | Fábio Fernandes | 2020-06-03 |
| Carpal Tunnel Syndrome and Amyloidosis (NCT04245098) | Corporacion Parc Tauli | 2020-01-08 |
| Amyloidosis Typing Using Mass Spectrometry-based Proteomics: a New Accurate Tool for Difficult Typing (NCT03984721) | University Hospital, Toulouse | 2019-07-25 |
| Screening for Systemic Amyloidosis Via the Ligamentum Flavum (NCT03923920) | The Cleveland Clinic | 2019-05-01 |
| Cardiac Amyloidosis Screening at Trigger Finger Release (NCT03886155) | The Cleveland Clinic | 2019-05-01 |
| Prevalence of Wildtype Amyloid After TAVR (NCT03825406) | North Florida Foundation for Research and Education | 2019-03-20 |
| Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (NCT03860935) | Eidos Therapeutics, a BridgeBio company | 2019-03-19 |
| Multiple Ascending Dose Study in Healthy Subjects (NCT03879278) | Proclara Biosciences, Inc. | 2019-03-06 |
| 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients (NCT03702829) | Brigham and Women's Hospital | 2019-02-28 |
| A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease (NCT03774784) | Alnylam Pharmaceuticals | 2019-01-29 |
| Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial (NCT03584022) | Mayo Clinic | 2018-11-09 |
| Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects (NCT03567499) | GlaxoSmithKline | 2018-07-12 |
| Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging (NCT03417830) | GlaxoSmithKline | 2018-04-06 |
| Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis (NCT03130348) | Mayo Clinic | 2018-03-15 |
| Registry for Adults With Plasma Cell Disorders (PCD's) (NCT03717844) | UNC Lineberger Comprehensive Cancer Center | 2018-02-09 |
| Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis (NCT03431896) | The Cleveland Clinic | 2018-02-01 |
| A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis (NCT03201965) | Janssen Research & Development, LLC | 2017-10-05 |
| A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis (NCT02545907) | University College, London | 2017-09-14 |
| Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698 (NCT03044353) | GlaxoSmithKline | 2017-07-10 |
| Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis (NCT03019029) | Mayo Clinic | 2017-03-13 |
| Ixazomib Rollover Study (NCT02924272) | Takeda | 2016-12-16 |
| Phase 1 Study of GSK2315698 in Healthy Japanese Subjects (NCT02953808) | GlaxoSmithKline | 2016-11-01 |
| Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. (NCT02909036) | Memorial Sloan Kettering Cancer Center | 2016-09-01 |
| Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis (NCT02816476) | University Hospital, Limoges | 2016-09-01 |
| A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis (NCT02603172) | GlaxoSmithKline | 2016-05-12 |
| Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis (NCT02338427) | Centre Hospitalier Departemental Vendee | 2016-05-01 |
| Carpal Tunnel Syndrome and Amyloid Cardiomyopathy (NCT02792790) | The Cleveland Clinic | 2016-03-01 |
| Carpal Tunnel/Amyloidosis Blood Sample Study (NCT02587728) | University of Miami | 2016-02-24 |
| The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart (NCT02627820) | Brigham and Women's Hospital | 2016-01-01 |
| Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis (NCT02590588) | John Mark Sloan | 2016-01-01 |
| Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant (NCT02589860) | Sherif S. Farag | 2015-10-30 |
| Quality of Life (QOL) Registry for Patients With AL Amyloidosis (NCT02574676) | Prothena Biosciences Ltd. | 2015-10-01 |
| Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis (NCT02555969) | Tufts Medical Center | 2015-08-01 |
| The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) (NCT02510261) | Alnylam Pharmaceuticals | 2015-07-16 |
| Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease (NCT02158052) | Massachusetts General Hospital | 2015-02-01 |
| German Centre for Cardiovascular Research Cardiomyopathy Register (NCT02187263) | Heidelberg University | 2014-12-01 |
| Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. (NCT02260466) | French Cardiology Society | 2014-10-01 |
| Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) (NCT02175004) | Ionis Pharmaceuticals, Inc. | 2014-06-26 |
| Vinorelbine and Gemcitabine in Myeloma (NCT02791373) | Insel Gruppe AG, University Hospital Bern | 2014-03-01 |
| Body Composition in Systemic Amyloidosis (NCT02111538) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2014-02-01 |
| Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging (NCT02462213) | University of Cincinnati | 2013-10-01 |
| Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis (NCT01864018) | Mayo Clinic | 2013-08-20 |
| A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis (NCT01777243) | GlaxoSmithKline | 2013-05-13 |
| Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy (NCT01737398) | Ionis Pharmaceuticals, Inc. | 2013-03-15 |
| A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis (NCT01789242) | Criterium, Inc. | 2013-02-01 |
| Safety and Effect of Doxycycline in Patients With Amyloidosis (NCT01677286) | Boston University | 2012-07-01 |
| SAP Depleter Dose Assessment Study in Patients (NCT01406314) | GlaxoSmithKline | 2011-10-13 |
| The Effect of Diflunisal on Familial Transthyretin Amyloidosis (NCT01432587) | Umeå University | 2011-08-01 |
| Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis (NCT01383759) | Memorial Sloan Kettering Cancer Center | 2011-06-24 |
| Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation (NCT01606280) | Mayo Clinic | 2011-06-01 |
| HIBA-Institutional Registry of Amyloidosis (NCT01347047) | Hospital Italiano de Buenos Aires | 2011-04-01 |
| Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL) (NCT01273844) | Zhi-Hong Liu, M.D. | 2011-03-01 |
| SAP Depleter Dose Escalation Study in Healthy Volunteers (NCT01323985) | GlaxoSmithKline | 2011-01-06 |
| Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis (NCT01215747) | C.T. Development America, Inc. | 2010-11-01 |
| Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis (NCT02485613) | Zhi-Hong Liu, M.D. | 2009-01-01 |
| B-Receptor Signaling in Cardiomyopathy (NCT01135849) | Daniel Bernstein | 2008-11-01 |
| Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) (NCT00981708) | University of Athens | 2008-02-01 |
| Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis (NCT00607581) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2008-02-01 |
| Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis (NCT00621400) | Nantes University Hospital | 2008-01-01 |
| Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis (NCT01998503) | Nanjing University School of Medicine | 2007-12-01 |
| Nutritional Counseling in Systemic Immunoglobulin Light-chain Amyloidosis (NCT02055534) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2007-07-01 |
| Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis (NCT00166413) | Mayo Clinic | 2005-04-01 |
| S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. (NCT00919139) | SWOG Cancer Research Network | 2003-11-01 |
| Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis (NCT01527032) | FDA Office of Orphan Products Development | 2002-09-01 |
| Mixed Chimeric Transplantation for Primary Amyloidosis (NCT00186095) | Stanford University | 2000-12-01 |
| Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis (NCT00017680) | Herbert Irving Comprehensive Cancer Center | 1999-07-01 |
| Study of Systemic Amyloidosis Presentation and Prognosis (NCT00004374) | National Center for Research Resources (NCRR) | 1979-01-01 |
| Expanded Access to Venetoclax (NCT03123029) | AbbVie | |